High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
BACKGROUND\r\nWe aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL).\r\nPATIENTS AND METHODS\r\nPatients aged 18-60 years and elevated lactate dehydrogenase were treated with four cycles of MegaCHOEP and transplantation of autologous stem cells after cycles 2, 3 and 4. Rituximab (375 mg/m²) was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaCHOEP were compared with 29 patients who had received identical treatment without rituximab.\r\nRESULTS\r\nOverall survival (OS) and event-free survival (EFS) after 3 years were significantly improved in patients treated with R-MegaCHOEP (OS: 78.7\% versus 55.0\%, P = 0.045; EFS: 72.7\% versus 47.2\%, P = 0.013). In a Cox regression model adjusted for performance status and stage, relative risk of treatment failure was lower (relative risk 0.5, P = 0.041) and OS was better (relative risk 0.4, P = 0.054) for patients given R-MegaCHOEP. Grade 3/4 infections were more frequent in the R-MegaCHOEP group (18.5\% versus 6.0\%, P = 0.003).\r\nCONCLUSIONS\r\nThe addition of rituximab to MegaCHOEP significantly improved outcome in young patients with high-risk DLBCL. The higher incidence of grade 3/4 infections needs consideration when rituximab and HDT regimens are combined.
%0 Journal Article
%1 Glass.2010
%A Glass, B.
%A Ziepert, Marita
%A Reiser, M.
%A Freund, M.
%A Trümper, L.
%A Metzner, B.
%A Feller, A.
%A Loeffler, Markus
%A Pfreundschuh, Michael
%A Schmitz, Norbert
%D 2010
%J Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
%K IMISE-Publikationen
%N 11
%P 2255–2261
%T High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
%V 21
%X BACKGROUND\r\nWe aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL).\r\nPATIENTS AND METHODS\r\nPatients aged 18-60 years and elevated lactate dehydrogenase were treated with four cycles of MegaCHOEP and transplantation of autologous stem cells after cycles 2, 3 and 4. Rituximab (375 mg/m²) was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaCHOEP were compared with 29 patients who had received identical treatment without rituximab.\r\nRESULTS\r\nOverall survival (OS) and event-free survival (EFS) after 3 years were significantly improved in patients treated with R-MegaCHOEP (OS: 78.7\% versus 55.0\%, P = 0.045; EFS: 72.7\% versus 47.2\%, P = 0.013). In a Cox regression model adjusted for performance status and stage, relative risk of treatment failure was lower (relative risk 0.5, P = 0.041) and OS was better (relative risk 0.4, P = 0.054) for patients given R-MegaCHOEP. Grade 3/4 infections were more frequent in the R-MegaCHOEP group (18.5\% versus 6.0\%, P = 0.003).\r\nCONCLUSIONS\r\nThe addition of rituximab to MegaCHOEP significantly improved outcome in young patients with high-risk DLBCL. The higher incidence of grade 3/4 infections needs consideration when rituximab and HDT regimens are combined.
@article{Glass.2010,
abstract = {BACKGROUND\r\nWe aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL).\r\nPATIENTS AND METHODS\r\nPatients aged 18-60 years and elevated lactate dehydrogenase were treated with four cycles of MegaCHOEP and transplantation of autologous stem cells after cycles 2, 3 and 4. Rituximab (375 mg/m²) was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaCHOEP were compared with 29 patients who had received identical treatment without rituximab.\r\nRESULTS\r\nOverall survival (OS) and event-free survival (EFS) after 3 years were significantly improved in patients treated with R-MegaCHOEP (OS: 78.7\% versus 55.0\%, P = 0.045; EFS: 72.7\% versus 47.2\%, P = 0.013). In a Cox regression model adjusted for performance status and stage, relative risk of treatment failure was lower (relative risk 0.5, P = 0.041) and OS was better (relative risk 0.4, P = 0.054) for patients given R-MegaCHOEP. Grade 3/4 infections were more frequent in the R-MegaCHOEP group (18.5\% versus 6.0\%, P = 0.003).\r\nCONCLUSIONS\r\nThe addition of rituximab to MegaCHOEP significantly improved outcome in young patients with high-risk DLBCL. The higher incidence of grade 3/4 infections needs consideration when rituximab and HDT regimens are combined.},
added-at = {2014-10-14T15:27:57.000+0200},
author = {Glass, B. and Ziepert, Marita and Reiser, M. and Freund, M. and Trümper, L. and Metzner, B. and Feller, A. and Loeffler, Markus and Pfreundschuh, Michael and Schmitz, Norbert},
biburl = {https://www.bibsonomy.org/bibtex/2cd4a4be5c23800f8a26c4fb5e21e2213/drtester},
interhash = {ae1ae0c1cead965caf4c62b3647be7e7},
intrahash = {cd4a4be5c23800f8a26c4fb5e21e2213},
journal = {Annals of oncology : official journal of the European Society for Medical Oncology / ESMO},
keywords = {IMISE-Publikationen},
number = 11,
pages = {2255–2261},
timestamp = {2014-12-03T00:08:27.000+0100},
title = {High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma},
volume = 21,
year = 2010
}